U.S. Post-Surgical Scar Treatment Market, by Product Type (Silicone sheets & Patches, Surgical tapes, Strips, Gels & Creams, and Others), by Channel (OTC, and Rx), by Scar Type (Atrophic Scars, Hypertrophic Scars, Keloid Scars, and Contracture Scars), by Surgery Type (Caesarean Section, Joint Replacement, Appendectomy, Heart Surgery, Breast surgery, and Other), and by End User (Ambulatory Surgical Centers, Clinics, Home Care Settings, and Hospitals), is estimated to be valued at US$ 2,680.1 million in 2022, and is expected to exhibit a CAGR of 10.1% during the forecast period (2022-2030).
Significant number of surgeries in the U.S., is expected to drive the growth of the U.S. post-surgical scar treatment market over the forecast period. According to the World Health Organization (WHO): 2021, cesarean delivery is the most common major surgical procedure performed in the U.S. Moreover, cesarean section are set to continue to increase over the coming decade, with nearly a third (29%) of all births likely to take place by caesarean section by 2030.
U.S. Post-Surgical Scar Treatment Market- Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Supply chain and manufacturing activities in the U.S. and other countries have been disrupted due to nationwide lockdowns. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the U.S. post-surgical scar treatment market during the forecast period